NCT06124807

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 179 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3305677 compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.

Conditions

• Obesity
• Overweight and Obesity

Interventions

Type	Name	Description
DRUG	LY3305677	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2023-11-17
• Primary completion: 2025-01-22
• Completion: 2025-07-09
• First posted: 2023-11-09
• Last updated: 2025-07-20

Locations

29 sites across 1 country: United States

Regulatory

• FDA-regulated drug study